{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Joly F"],"funding":["AstraZeneca"],"pagination":["7950"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12381027"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(1)"],"pubmed_abstract":["Single-agent maintenance poly(ADP-ribose) polymerase (PARP) inhibition may represent an effective strategy in patients with advanced/metastatic endometrial cancer responding to platinum-based chemotherapy, including for molecular subtypes with suboptimal options. To explore this approach, we initiated the randomized phase IIb UTOLA trial (NCT03745950). Female patients without progression following front-line platinum-based chemotherapy for advanced/metastatic endometrial cancer were randomized 2:1 to twice-daily maintenance oral olaparib 300 mg or placebo until progression or intolerance, stratified by p53 status, mismatch repair status, and response to initial chemotherapy. The primary endpoint was progression-free survival (PFS) in the intention-to-treat population. Secondary endpoints w"],"journal":["Nature communications"],"pubmed_title":["Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial."],"pmcid":["PMC12381027"],"funding_grant_id":["N/A"],"pubmed_authors":["Kaczmarek E","Arnaud A","Hardy Bessard AC","Rodrigues M","Joly F","Asselain B","Bonnet E","Jeanne C","Cojean-Zelek I","Gladieff L","Roche S","Meunier J","Bengrine Lefevre L","Fabbro M","Fernandez Diez Y","Leroy K","Callens C","Fournel P","Largillier R","Frenel JS","Abadie-Lacourtoisie S","Lebreton C","Ray-Coquard I","Leary A","Meynard G","Leman R","Follana P","Foa C","Alexandre J","Just PA","Selle F","You B"],"additional_accession":[]},"is_claimable":false,"name":"Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial.","description":"Single-agent maintenance poly(ADP-ribose) polymerase (PARP) inhibition may represent an effective strategy in patients with advanced/metastatic endometrial cancer responding to platinum-based chemotherapy, including for molecular subtypes with suboptimal options. To explore this approach, we initiated the randomized phase IIb UTOLA trial (NCT03745950). Female patients without progression following front-line platinum-based chemotherapy for advanced/metastatic endometrial cancer were randomized 2:1 to twice-daily maintenance oral olaparib 300 mg or placebo until progression or intolerance, stratified by p53 status, mismatch repair status, and response to initial chemotherapy. The primary endpoint was progression-free survival (PFS) in the intention-to-treat population. Secondary endpoints w","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-05-29T19:29:57.104Z","creation":"2026-04-08T05:44:39.502Z"},"accession":"S-EPMC12381027","cross_references":{"pubmed":["40858558"],"doi":["10.1038/s41467-025-62678-x"]}}